Docoh
Loading...

ADTX Aditx Therapeutics

Filed: 3 May 21, 5:28pm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 3, 2021

 

Aditx Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware 001-39336 82-3204328
(State or other jurisdiction
of incorporation)
 (Commission File Number) (IRS Employer
Identification No.)

 

2569 Wyandotte St., Suite 101

Mountain View, CA

 94043
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (909) 488-0844

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.001 ADTX The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

  

 

 

Item 8.01  Other Events.

  

On May 3, 2021, Aditx Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s intention to build a state-of-the-art high capacity AditxtScore™ immune monitoring center in Richmond, Virginia in the second half of 2021. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

  

Item 9.01  Financial Statements and Exhibits

  

Exhibits

  

Exhibit No. Description
99.1 Press release, dated May 3, 2021

  

 2 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 ADITX THERAPEUTICS, INC.
   
Date: May 3, 2021By:/s/ Corinne Pankovcin
  Corinne Pankovcin
  Chief Financial Officer

 

 

3